Conference Presentation

CervoMed posts first 80 mg neflamapimod data in Lewy body dementia

The Phase 2 dose-finding trial met its safety and pharmacokinetic goals, and CervoMed says the result sets the dose for a planned Phase 3 program in a disease with no approved treatment.

By AppliedXLJuly 14, 2026Trial NCT06815965

Executive Summary

CervoMed disclosed the first clinical data on its higher, twice-daily dose of neflamapimod in dementia with Lewy bodies, reporting that the regimen was tolerated and hit its pharmacokinetic targets.
The result lands directly ahead of a named Phase 3 program and appears to have shaped the dose CervoMed says it will carry forward, in a disease that still has no approved treatment.
The trial was designed to answer safety and exposure questions, not to demonstrate a clinical benefit, so any cognitive or functional signals reported alongside it are descriptive rather than definitive.
Neflamapimod has effectively no direct competitor working the same target in this indication, so the readout mainly extends the sponsor's own prior evidence rather than resolving a contested field.

The disclosure

CervoMed presented results from NCT06815965, a Phase 2 open-label study of neflamapimod 80 mg given twice daily in patients with probable dementia with Lewy bodies, at the AAIC meeting in London on July 14, 2026. The trial enrolled 26 patients across sites in France and completed in April 2026 after running from October 2024. Its four primary endpoints were safety, tolerability, and the trough and peak plasma concentrations of the 80 mg dose, not a cognitive or functional outcome. CervoMed said the regimen was well tolerated and achieved its target trough concentrations, with descriptive secondary signals of stabilization in executive function and global cognition. NCT06815965+1

Probability of Success

Endpoint Met11%

Completes95%

Clinical Significance21%

Regulatory59%

The design

The study was a single-arm, open-label trial with no placebo comparator, run in an elderly population with probable DLB and a required reliable caregiver or informant. Its secondary endpoints tracked change from baseline at 24 weeks on the CDR-Sum of Boxes, a Timed Up and Go motor test, and an Alzheimer's Disease Neuroimaging Initiative executive-function composite. An open-label, uncontrolled design of this size can establish tolerability and drug exposure. It cannot on its own establish a treatment effect, since there is no control arm to isolate the drug's contribution from natural variation or expectation. NCT06815965

Dose readthrough

CervoMed said the trial's pharmacokinetic and safety findings informed selection of a 50 mg three-times-daily dose for a planned Phase 3 program, and that the company has aligned with the FDA, EMA, MHRA, and PMDA on that program's design. That sequencing, an open-label dose-finding study feeding a named late-stage dose, is the direct consequence of this data: it moves neflamapimod from dose selection toward a registrational design rather than testing a new hypothesis about the drug itself. CervoMed

The competitive field

The MAPK14-targeting p38 alpha kinase inhibitor class has no other completed or active trial pairing this target with dementia with Lewy bodies besides CervoMed's own prior study, NCT05869669, and one Alzheimer's program from Neurokine Therapeutics testing MW150 against the same target. Other DLB programs in clinical testing, including Eisai's donepezil work, Lundbeck's memantine studies, and Eli Lilly's mevidalen, target acetylcholinesterase, NMDA receptors, or dopamine receptors rather than p38 MAP kinase, so none of them speak directly to this mechanism's tolerability or dosing. Dementia with Lewy bodies has no approved disease-modifying treatment, and standard-of-care options only manage symptoms, so a dose-finding result that clears safety and exposure targets removes one of the operational preconditions, not the efficacy question, for a program trying to advance a new mechanism into that gap. NCT06815965

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.